文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

撒哈拉以南非洲HIV感染者奈韦拉平超敏反应的全基因组关联研究

Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

该研究在马拉维成人HIV感染者中发现队列(151例超敏、182例耐受)中开展GWAS,并在马拉维、乌干达和莫桑比克116例病例与68例对照中验证。结果显示HLA-C*04:01 predisposes to nevirapine-induced SJS/TEN,OR 4.84(95%CI 2.71-8.61),但不与其他超敏表型相关,ERAP2可能起保护作用。

要点

  • HLA-C*04:01是奈韦拉平诱导SJS/TEN的易感因素,OR 4.84(95%CI 2.71-8.61)。
  • HLA-C*04:01不增加其他奈韦拉平超敏表型风险。
  • ERAP2变异可能降低风险(P=0.019,OR 0.43,95%CI 0.21-0.87),需进一步研究。

核心结论

  • HLA-C*04:01 predisposes to nevirapine-induced SJS/TEN in sub-Saharan Africans, but not to other hypersensitivity phenotypes.

研究设计与样本

  • 发现队列为151例奈韦拉平超敏和182例耐受的马拉维HIV感染成人,开展GWAS。
  • 验证队列为来自马拉维、乌干达和莫桑比克的116例病例和68例对照。
  • 对HLA-C*04:01阳性患者检测ERAP基因交互作用,并进行HLA-C*04:01的计算机对接研究。

主要发现

  • 15个SNP与一个或多个超敏表型达到名义显著性(P < 1 × 10^-5)。
  • SJS/TEN中最有希望的信号为rs5010528(HLA-C位点),接近全基因组显著性(P < 8.5 × 10^-8),在发现与验证队列meta分析中低于HLA-wide显著性(P < 2.5 × 10^-4),OR 4.84(95% CI 2.71-8.61)。
  • rs5010528是HLA-C*04:01携带的强代理,计算机对接显示B口袋的第33和123位残基最可能是奈韦拉平相互作用位点。
  • HLA-C*04:01与ERAP1无交互作用,但与ERAP2存在潜在保护效应(P = 0.019,OR 0.43(95% CI 0.21-0.87))。

临床怎么用

  • 在撒哈拉以南非洲HIV感染者中,HLA-C*04:01检测可能有助于识别奈韦拉平诱导SJS/TEN高风险患者。
  • HLA-C*04:01不预示其他奈韦拉平超敏反应,临床决策需结合其他因素。

局限性

  • ERAP2变异对风险的调节作用尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The antiretroviral nevirapine is associated with hypersensitivity reactions in 6%-10% of patients, including hepatotoxicity, maculopapular exanthema, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). OBJECTIVES: To undertake a genome-wide association study (GWAS) to identify genetic predisposing factors for the different clinical phenotypes associated with nevirapine hypersensitivity. METHODS: A GWAS was undertaken in a discovery cohort of 151 nevirapine-hypersensitive and 182 tolerant, HIV-infected Malawian adults. Replication of signals was determined in a cohort of 116 cases and 68 controls obtained from Malawi, Uganda and Mozambique. Interaction with ERAP genes was determined in patients positive for HLA-C*04:01 . In silico docking studies were also performed for HLA-C*04:01 . RESULTS: Fifteen SNPs demonstrated nominal significance ( P < 1 × 10 -5 ) with one or more of the hypersensitivity phenotypes. The most promising signal was seen in SJS/TEN, where rs5010528 ( HLA-C locus) approached genome-wide significance ( P < 8.5 × 10 -8 ) and was below HLA -wide significance ( P < 2.5 × 10 -4 ) in the meta-analysis of discovery and replication cohorts [OR 4.84 (95% CI 2.71-8.61)]. rs5010528 is a strong proxy for HLA-C*04:01 carriage: in silico docking showed that two residues (33 and 123) in the B pocket were the most likely nevirapine interactors. There was no interaction between HLA-C*04:01 and ERAP1 , but there is a potential protective effect with ERAP2 [ P = 0.019, OR 0.43 (95% CI 0.21-0.87)]. CONCLUSIONS: HLA-C*04:01 predisposes to nevirapine-induced SJS/TEN in sub-Saharan Africans, but not to other hypersensitivity phenotypes. This is likely to be mediated via binding to the B pocket of the HLA-C peptide. Whether this risk is modulated by ERAP2 variants requires further study.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Carr DF, Bourgeois S, Chaponda M, et al. Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population. J Antimicrob Chemother. 2017. PMID: 28062682. doi:10.1093/jac/dkw545

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。